Compare QBTS & CYTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | QBTS | CYTK |
|---|---|---|
| Founded | 1999 | 1997 |
| Country | | US |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.8B | 8.0B |
| IPO Year | N/A | 2004 |
| Metric | QBTS | CYTK |
|---|---|---|
| Price | $19.15 | $67.52 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 15 | 17 |
| Target Price | $32.80 | ★ $85.24 |
| AVG Volume (30 Days) | ★ 26.7M | 1.5M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 3.49 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $13,368,000.00 |
| Revenue This Year | $196.28 | $341.94 |
| Revenue Next Year | $54.79 | $50.15 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $4.45 | $29.31 |
| 52 Week High | $46.75 | $70.98 |
| Indicator | QBTS | CYTK |
|---|---|---|
| Relative Strength Index (RSI) | 40.04 | 58.52 |
| Support Level | $17.81 | $64.58 |
| Resistance Level | $19.62 | $67.67 |
| Average True Range (ATR) | 1.78 | 2.73 |
| MACD | -0.05 | 0.37 |
| Stochastic Oscillator | 35.48 | 94.32 |
D-Wave Quantum Inc is in the development and delivery of quantum computing systems, software, and services, and it is the commercial supplier of quantum computers and the only company building both annealing quantum computers and gate-model quantum computers. It delivers customer value with practical quantum applications for problems as diverse as logistics, artificial intelligence, materials sciences, drug discovery, scheduling, cybersecurity, fault detection, and financial modeling. Its annealing quantum computers are accessible through the company's LeapTM cloud service.
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.